Enzyme blends, particularly those containing proteolytic enzymes such as bromelain, serrapeptase, or trypsin, have been investigated for their potential in managing edema, especially post-surgical or traumatic edema. The scientific basis for their use lies in their ability to break down proteins involved in inflammatory processes and fibrin deposition, which can contribute to swelling. Several clinical studies, particularly in Europe and Asia, have reported that oral proteolytic enzyme supplements can reduce the severity and duration of edema following surgery or injury. For example, randomized controlled trials have found that bromelain and serrapeptase may help decrease swelling and inflammation after dental or orthopedic procedures.

However, the overall quality and quantity of evidence is moderate, with many studies having methodological limitations such as small sample sizes, lack of blinding, or inconsistent dosing protocols. Meta-analyses suggest a positive effect, but also emphasize the need for larger, well-designed trials to confirm these findings. The mechanisms proposed include enhanced fibrinolysis, reduction of inflammatory mediators, and improved microcirculation. While enzyme blends are generally considered safe, they can interact with certain medications and may not be appropriate for all patients. In summary, there is scientific validation for the use of enzyme blends in the management of specific types of edema, but more robust clinical evidence is needed to establish their efficacy and safety profile for broader use.